{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:13:34Z","timestamp":1788225214985,"version":"build-2803163510"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2023,10,17]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    To assess the feasibility of oral fosfomycin-tromethamine (FT) for the management of acute bacterial prostatitis (ABP) caused by multidrug-resistant (MDR) Enterobacterales. An observational study of adult patients diagnosed with ABP from Vall d\u2019Hebron University Hospital (Barcelona, Spain), treated with oral FT. The primary outcome was clinical cure defined as symptom relief at the control visit, 2\u20134 weeks post-end of treatment. Secondary outcomes included microbiological cure, relapse, and adverse events related to the treatment. Eighteen patients with ABP caused by Enterobacterales (15\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    and three\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    ) were included. Microorganisms were MDR bacteria [14 extended-spectrum beta-lactamase (ESBL) producers and two carbapenemase producing\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    ]. Patients received treatment with FT 3 g\/48 hours during a median of 14 days (Q25\u2013Q75, 12\u201317.75). Fifteen patients received a lead-in phase of intravenous suitable antimicrobial during a median of 7 days (Q25\u2013Q75, 3.75\u20138). No patient had to stop treatment due to adverse events, and the only side effect reported in two patients was diarrhea. Clinical cure was achieved in all (18\/18) patients and microbiological cure in 11\/12 patients. After a median of follow-up of 5 months (Q25\u2013Q75, 2\u201311), 2\/18 patients relapsed with an orchitis and a new episode of ABP. FT is an attractive step-down therapy for ABP in patients with resistance or side effects to first-line drugs. The availability of oral treatment could reduce the use of the carbapenems, with a benefit in the quality of life of the patient, health costs, and an ecological impact.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>IMPORTANCE<\/jats:title>\n                    <jats:p>We present a brief but largest and interesting experience in which we use fosfomycin-tromethamine (FT) for the treatment of acute bacterial prostatitis (ABP) due to multiresistant bacteria. Our study provides new data that help to consider FT as a plausible alternative for treating ABP in patients with resistance or side effects to first-line drugs. The availability of an alternative oral treatment to avoid the use of the carbapenems could have important benefits in terms of quality of life of the patient, health costs, and an ecological impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.02136-23","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:03:41Z","timestamp":1695373421000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Oral fosfomycin for treatment of acute bacterial prostatitis caused by multidrug-resistant Enterobacterales"],"prefix":"10.1128","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8445-3047","authenticated-orcid":false,"given":"Joaquin","family":"Burgos","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d'Hebron. Vall d'Hebron Research Institute (VHIR). Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Hoyos-Mallecot","sequence":"additional","affiliation":[{"name":"Microbiological Department, Hospital Universitari Vall d'Hebron. Vall d'Hebron Research Institute (VHIR). Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Ferre-Losa","sequence":"additional","affiliation":[{"name":"Emergency Department, Hospital Universitari Vall d'Hebron. Vall d'Hebron Research Institute (VHIR). Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maider","family":"Arando","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d'Hebron. Vall d'Hebron Research Institute (VHIR). Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnau","family":"Monforte","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d'Hebron. Vall d'Hebron Research Institute (VHIR). Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Pumarola","sequence":"additional","affiliation":[{"name":"Microbiological Department, Hospital Universitari Vall d'Hebron. Vall d'Hebron Research Institute (VHIR). Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibai","family":"Los-Arcos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d'Hebron. Vall d'Hebron Research Institute (VHIR). Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d'Hebron. Vall d'Hebron Research Institute (VHIR). Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"114","article-title":"Acute bacterial prostatitis: diagnosis and management","volume":"93","author":"Coker TJ","year":"2016","unstructured":"Coker TJ , Dierfeldt DM . 2016. Acute bacterial prostatitis: diagnosis and management. Am Fam Physician 93:114\u2013120.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/652861"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00534-21"},{"key":"e_1_3_2_5_2","article-title":"FORECAST study team. Fosfomycin versus ciprofloxacin as oral stepdown treatment for Escherichia coli febrile urinary tract infection in women: a randomized, placebo-controlled, double blind, multicenter trial","author":"Ten Doesschate T","year":"2021","unstructured":"Ten Doesschate T , Kuiper S , van Nieuwkoop C . 2021. FORECAST study team. Fosfomycin versus ciprofloxacin as oral stepdown treatment for Escherichia coli febrile urinary tract infection in women: a randomized, placebo-controlled, double blind, multicenter trial. Clin Infect Dis:ciab934.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit704"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.020"},{"key":"e_1_3_2_8_2","unstructured":"European Committee on antimicrobial susceptibility testing. 2023. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.0_Breakpoint_Tables.pdf"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa126"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37277"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02611-15"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz015"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020198"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02136-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02136-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:22:11Z","timestamp":1788222131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.02136-23"}},"subtitle":[],"editor":[{"given":"Karen C.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10,17]]}},"alternative-id":["10.1128\/spectrum.02136-23"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.02136-23","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"2023-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02136-23"}}